Brian joined Domain in 2001 and became a partner in 2006. He has been involved with new company creation and in establishing and directing Domain’s new initiative in China in collaboration with Beijing Elite. Present board memberships include Alimera Sciences, BioNano Genomics, Carticept Medical, Dicerna Pharmaceuticals, Kona Medical, Medico (Hong Kong) Limited, Zyga Technology and WindMIL Therapeutics, where he is also acting President and CEO. He previously served on the boards of Eddingpharm, Esprit Pharma (until acquired by Allergan), GI Dynamics and Vanda Pharmaceuticals.
Prior to Domain, Brian was an associate with Advanced Technology Ventures where he participated in the firm’s investments in Plexxikon, Percardia and Emphasys. Previous to that, he was a consultant at the Wilkerson Group, where he developed strategy for pharmaceutical and medical device companies. Brian received his BSE in bioengineering from University of Pennsylvania and his Ph.D. in immunology from Thomas Jefferson University.
Brian is currently a member of the Advisory Board for the Department of BioEngineering of the University of Pennsylvania, an advisor to Elm Street Ventures, and a director on the board of Pennsylvania BIO.
Immanuel Thangaraj has 18 years of experience in operations and venture capital. Mr. Thangaraj began his venture career at ARCH Venture Partners (“AVP”), a leading venture capital firm with over $2 billion under management which makes early stage technology and healthcare investments. During his tenure at AVP, he managed one of its portfolio companies, HealthQual, a medical information company, until its sale to Nellcor, a large hospital supplies company. Mr. Thangaraj left AVP in 1995 to run a start-up telecommunications services company called Integrated Telemanagement, which was later sold to Cam-Net Communications.
In addition to the portfolio company boards on which he serves, Mr. Thangaraj is also responsible for Essex Woodlands’ investment in two Chinese companies, Microport Scientific Corporation (HK:853) and China Cord Blood Services Corporation (NYSE: CO).
Mr. Thangaraj also serves as the Chairman of the Board of Directors for MAP International, is an Advisory Board member for the University of Chicago’s Polsky Center for Entrepreneurship, is an Advisory Board member of the Global Cardiovascular Innovation Center (GCIC) at the Cleveland Clinic. In addition, Mr. Thangaraj is a Trustee of Trinity School in Menlo Park, California and on the board of the India Community Center.
Mr. Thangaraj joined Essex Woodlands as a Partner in 1996, and was promoted to Managing Director in 1998.
Lori Hu joined the Vertex Ventures HC Palo Alto office in 2015 focusing on global healthcare investments. Prior to Vertex, Lori was an Associate Director for Business Development at Bristol-Myers Squibb, identifying and executing licensing, partnerships and transactions for the Chinese market. She has also worked with SR One, the corporate venture capital arm of GlaxoSmithKline in Boston. Previously, she was a strategy consultant in the health & life sciences practice at Accenture based across Singapore, China and South Africa.
Lori graduated with an MBA from The Wharton School, and MA in International Studies from the University of Pennsylvania where she was a Leonard Lauder Fellow. She also holds a BSE in Biomedical Engineering from Duke University.